Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes

1 Jun 2022

Abstract excerpt

BACKGROUND: Targeted drugs have greatly improved the therapeutic outcome of non-small cell lung cancer (NSCLC) patients compared with conventional chemotherapy, whereas about one-third of patients are so far not suitable for targeted therapy due to lack of known driver oncogenes such as a mutated receptor tyrosine kinase (RTK) genes. In this study, we aimed to identify therapeutic targets for this subgroup of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to CRISPR and Genetic Engineering
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35692096
DOI: 10.1002/ctm2.882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genesPMID 35692096Read ↗

A Novel TP53 Gene Mutation Sustains Non-Small Cell Lung Cancer through Mitophagy.Semantic proximity Read ↗

Functional diversity of the <i>TP53</i> mutome revealed by saturating CRISPR mutagenesisSemantic proximity Read ↗

CRISPR-mediated modulation of EGFR signaling in lung cancer.Semantic proximity Read ↗

Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancerSemantic proximity Read ↗

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?Semantic proximity Read ↗

The Development of p53-Targeted Therapies for Human CancersSemantic proximity Read ↗

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.Semantic proximity Read ↗

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.Semantic proximity Read ↗

Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells.Semantic proximity Read ↗

Loss of mutant TP53 does not impair the sustained proliferation, survival or metastasis of diverse cancer cellsSemantic proximity Read ↗

CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer.Semantic proximity Read ↗

Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.